Does Insurance Cover Bijuva? What 10 Current Insurance Documents Show in 2026

The HRT Index Editorial TeamIndependent women's health research

Published: May 15, 2026Last reviewed: August 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: August 3, 2026 · Last verified: August 3, 2026 · U.S. insurance coverage only. Editorial research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

If this coverage question is part of a bigger decision

The free Find My HRT Path tool can compare your state, insurance situation, medication-route preference, and safety flags before you pay for online care or change treatment.

Find My HRT Path

By The HRT Index Editorial Team · Last verified August 3, 2026 · U.S. insurance coverage only

Editorial research. This page is not medical advice and was not medically reviewed by a clinician. See our medical review policy.

Does insurance cover Bijuva? Sometimes. In 10 current insurance documents checked in August 2026, Bijuva ranged from excluded, to a preferred option, to Tier 2 or Tier 3 with different restrictions. Your exact pharmacy benefit—not the insurer logo alone—determines coverage, prior authorization, and what you pay.

Same drug. Same year. Different verdicts. The Express Scripts National Preferred Formulary exclusion list excludes Bijuva. The Aetna Advanced Control Plan exclusion list names Bijuva as a preferred option for several excluded products. The Optum Rx Premium Formulary places it at Tier 3 with no restriction code displayed on the row.

Here is the part almost nobody tells you: Bijuva is not always the expensive brand a plan is pushing you away from. On one current list, it is a product the plan points members toward. On another, it is excluded. On three state-specific UnitedHealthcare lists, it carries different strength-level restrictions.

Best case: your exact plan lists Bijuva without a prior-authorization, step-therapy, or quantity-limit code on the public row. Hard case: it is listed but restricted or expensive. Worst case: it is excluded, and the commercial copay card cannot create coverage that the plan has not approved.

Is this page for you?

This page is for you if	This page is not for you if
You have a Bijuva prescription and do not know whether your plan will pay	You are deciding whether Bijuva is medically right for you—that belongs with your prescriber
Your pharmacy quoted a high price or returned a rejection	You want one national copay or coverage percentage—no public national dataset supports one
You received a denial and need the correct next step	You need urgent medical help
You use commercial insurance, Medicare, Medicaid, or cash and need the right affordability route	You want a compounded product presented as generic or equivalent to Bijuva—it is not

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Find your lane in 10 seconds

Your situation	The bottom line	Your first move
Commercial, employer, or marketplace plan	Coverage depends on the exact benefit. The current commercial card can reduce an eligible covered claim; it cannot create coverage.	Find the plan or PBM name near the RxBIN and RxPCN, then check the member formulary
Medicare Part D or Medicare Advantage with drug coverage	The commercial card is not valid. A separate Bijuva program exists, but it requires opting out of the Part D benefit for Bijuva for the rest of the calendar year.	Compare your covered price, exception route, and opt-out consequences before enrolling
Medicaid	Coverage is state- and plan-specific. Two 2026 Medicaid documents we checked cover Bijuva with different restrictions. The commercial card is not valid for Medicaid.	Use your state plan's current drug list and pharmacy-benefit phone number
Uninsured or paying cash	Neither the commercial card nor the Medicare Part D program applies. A cash or discount price is location-, pharmacy-, and session-specific.	Get current quotes from several pharmacies before paying

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

What did we actually verify?

We opened the current documents below, checked their scope and effective dates, and read the Bijuva row or Bijuva-specific coverage criteria. The result is a reproducible cross-plan dataset—not a survey, national coverage estimate, or promise about any reader's claim.

#	Current insurance document	Effective or current date shown	What the document shows for Bijuva	What it does not prove
1	Express Scripts National Preferred Formulary exclusions	Effective in 2026; document dated July 1, 2026	Bijuva is excluded; estradiol/norethindrone acetate and ethinyl estradiol/norethindrone acetate are listed as preferred alternatives	That every Express Scripts plan excludes it
2	Aetna Advanced Control Plan exclusions	July 2026	Bijuva is a preferred option for excluded Angeliq, Duavee, Premphase, and Prempro	Bijuva's tier, member price, or coverage under every Aetna plan
3	Optum Rx Premium Formulary	Effective January 1, 2026	Tier 3; no PA, ST, or QL code is displayed on the Bijuva row	The member's copay or an employer-specific guarantee
4	Independence Blue Cross Premium Formulary	Effective July 1, 2026	Tier 3; no restriction code is displayed on the Bijuva row	Coverage under another Blue plan
5	UnitedHealthcare Commercial Prescription Drug List	Effective January 1, 2026	Tier 3; no restriction code is displayed on the Bijuva row	Coverage under every UnitedHealthcare employer plan
6	UnitedHealthcare Community Plan of Michigan Medicaid PDL	Effective May 1, 2026	Both strengths are Tier 2 with PA; the 1 mg/100 mg strength also has QL	Another state's Medicaid rule
7	UnitedHealthcare Washington Apple Health PDL	Effective July 1, 2026	Both strengths are Tier 2 with PA and QL; the 0.5 mg/100 mg strength also has an age-limit code	Another UnitedHealthcare plan's restrictions
8	UnitedHealthcare New York Essential Plan PDL	Effective July 1, 2026	The 1 mg/100 mg strength is Tier 2 with PA and QL; the 0.5 mg/100 mg strength was not shown in the reviewed row	That the unlisted strength is categorically excluded
9	FEP Blue Basic Medicare Prescription Drug Program formulary	2026 formulary; updated September 19, 2025	Both strengths are Tier 3 with no requirement displayed on the rows	Coverage under other FEP, Blue, Part D, or Medicare Advantage plans
10	Mass General Brigham Health Plan commercial and exchange PA policy	Effective September 1, 2025; still published when checked August 3, 2026	Bijuva requires PA under this policy; one route requires inadequate response, intolerance, or contraindication to estrogen and progesterone taken concurrently as separate agents; approvals are 12 months	That every plan uses the same criteria

What we could not verify—and will not pretend we did

We do not know what percentage of U.S. plans cover Bijuva. No representative public national dataset was found.
We did not run a member-specific pharmacy claim.
A blank restriction column in a public formulary does not override an employer amendment, benefit exclusion, or member-specific rule.
We did not verify one national cash price or one national Bijuva copay. Those numbers depend on the exact pharmacy, location, plan, deductible, and claim.
We did not verify that the FDA-approved Amneal generic is currently orderable through any particular pharmacy or wholesaler.
We did not verify that any specific telehealth provider will prescribe Bijuva, continue an existing prescription, submit prior authorization, or handle an appeal.

That is the damaging admission at the center of this page: even 10 current documents cannot tell you what your own claim will do. They can show you what is possible, expose the rules that matter, and stop you from wasting time on the wrong route.

→ Use the Bijuva Coverage Decoder

Does insurance cover Bijuva in 2026?

Some plans cover Bijuva, some restrict it, and some exclude it. The decisive source is the exact pharmacy benefit attached to your membership—not a carrier logo, a general drug page, or a formulary from a different employer, state, or plan design.

Four separate questions determine the real answer:

Layer	The question	Why it changes your result
Formulary position	Is Bijuva listed, preferred, non-preferred, or excluded?	This determines whether a normal covered claim is even possible
Utilization management	Does the exact strength have PA, ST, QL, or another limit?	A listed drug can still reject until the requirement is satisfied
Cost sharing	What tier, deductible, copay, or coinsurance applies?	A covered drug can still be unaffordable
Claim adjudication	What happened when the pharmacy submitted the exact prescription and package code?	This is where the plan, pharmacy, strength, day supply, and current NDC meet

The same UnitedHealthcare name produced four different public results

UnitedHealthcare document	Public Bijuva result
Commercial PDL	Tier 3; no restriction code displayed
Michigan Medicaid	Both strengths Tier 2 with PA; 1 mg/100 mg also QL
Washington Apple Health Medicaid	Both strengths Tier 2 with PA and QL; 0.5 mg/100 mg also age-limited
New York Essential Plan	1 mg/100 mg Tier 2 with PA and QL; 0.5 mg/100 mg not shown in the reviewed row

That is why “Does UnitedHealthcare cover Bijuva?” is not a complete question. Neither is “Does CVS cover it?” or “Does Blue Cross cover it?” You need the exact plan name, benefit design, and strength.

The PBM name still helps. It tells you which company may administer the drug benefit and which member portal or phone line to use. It does not erase employer, state, union, Medicare, Medicaid, or plan-specific variation.

What do “covered,” “preferred,” “Tier 3,” and “excluded” mean?

Insurance documents use words that sound interchangeable but trigger different solutions. “Listed” does not establish member coverage, “covered” does not establish affordability, and “preferred” does not establish clinical equivalence.

Term	What it means here	What you still need to know
Listed	Bijuva appears in a drug document	Whether that document governs your exact benefit
Covered	The drug can be adjudicated under the benefit, subject to its rules	Deductible, cost share, restrictions, pharmacy network, and strength
Preferred	The document favors Bijuva relative to another product	Tier, restrictions, and whether the preference applies to your plan
Tier 2 or Tier 3	A plan-specific cost-sharing position	The actual dollar copay or coinsurance under your benefit
PA, ST, or QL	Prior authorization, step therapy, or quantity limit	The exact criteria and who must submit the request
Excluded	The normal formulary route does not cover the drug	Whether a formulary exception or appeal is available
Affordable	The amount you actually owe after the claim is processed	Whether assistance applies and whether the transaction counts toward your deductible or out-of-pocket total

Aetna's current exclusion document makes this distinction explicit: it calls Bijuva a preferred option for several excluded drugs but also says its preferred options do not necessarily represent clinical equivalency. The paperwork can favor a product without declaring it medically interchangeable. Aetna Advanced Control Plan exclusions

The word that matters is the one attached to your benefit. Everything else is background.

How can Bijuva be preferred on one list and higher-tier on another?

The Aetna Advanced Control Plan exclusion list points members from several excluded products toward Bijuva, while the Optum Rx Premium Formulary puts Bijuva at Tier 3 and places several of those products at Tier 2. The two current documents create opposite financial signals around the same medicines.

Product	Aetna Advanced Control Plan, July 2026	Optum Rx Premium Formulary, 2026
Bijuva	Preferred option for several excluded products	Tier 3
Duavee	Excluded; Bijuva is one listed option	Tier 2
Premphase	Excluded; Bijuva is one listed option	Tier 2
Prempro	Excluded; Bijuva is one listed option	Tier 2
Estradiol/norethindrone acetate	Preferred option	Tier 1

Read the Bijuva row across. On one current document it is part of the destination. On the other it sits one tier above products it replaces elsewhere.

This destroys the lazy rule that “brand-name menopause drugs are never covered.” It also destroys the opposite rule that Bijuva is broadly preferred. Both shortcuts fail.

Here is what the documents do not tell us: why a particular sponsor selected that arrangement or what medical decision is right for an individual woman. We report the row. We do not invent the motive.

What does one real 2026 formulary put around Bijuva?

The Optum Rx Premium Formulary places generic hormone products largely at Tier 1, several established brands at Tier 2, and Bijuva with several other brands at Tier 3. That is one plan template—not a national ranking—but it shows the cost ladder a member can face.

Tier in the Optum Rx Premium Formulary	Menopause-relevant examples in the document
Tier 1	Estradiol oral, transdermal, and vaginal; estradiol/norethindrone acetate; oral progesterone; Dotti; Lyllana; Mimvey; Yuvafem
Tier 2	Climara Pro; Duavee; Imvexxy starter and maintenance packs; Premarin oral and vaginal; Premphase; Prempro
Tier 3	Bijuva; Divigel; Elestrin; Evamist; Osphena

The Bijuva row has no PA, ST, or QL notation in this public document. That does not guarantee an unrestricted member claim, but it proves that prior authorization is not universal across every public 2026 formulary.

The same booklet says drugs may move to a higher tier or become excluded on January 1 or July 1. If Bijuva is working under your current benefit, recheck the formulary around plan-year renewal and midyear updates rather than discovering the change at the pharmacy. Optum Rx Premium Formulary

Bijuva Coverage Decoder

Use the exact message from your member portal, plan, or pharmacy. Do not treat every rejection as a denial.

What you see	What it may mean	Your next move
Bijuva is listed with a tier and no code	The public row shows no PA, ST, or QL requirement	Run the exact prescription through the member pricing tool or pharmacy; confirm deductible and network
PA required	The plan wants supporting information before it will cover the claim	Get the current PA criteria and ask the prescriber's office whether it will submit
ST required	The plan requires another covered option or documented history first	Get the exact step rule in writing; do not guess what counts
QL shown	The plan limits the amount or day supply	Confirm the prescribed quantity and ask whether a quantity exception is available
Excluded or non-formulary	The ordinary formulary route does not cover Bijuva	Request the exception criteria; compare appeal versus a prescriber-approved covered option
Covered but expensive	Tier, deductible, coinsurance, pharmacy, or day supply is driving the amount	Compare preferred-pharmacy, mail-order, eligible commercial-card, and cash prices separately
Deductible not met	The drug may be covered while you remain responsible for the negotiated amount	Confirm the remaining pharmacy deductible and whether the claim was processed correctly
NDC not covered	The submitted package code may not match the plan's current file	Ask which NDC was billed and have the pharmacist verify the current package code
Not found	Wrong spelling, wrong strength, outdated list, or a non-formulary result is possible	Search both strengths, then call the number on the prescription card
Refill too soon or out of network	An administrative rule blocked the claim	Ask for the eligible fill date or an in-network pharmacy

The decoder does not decide medical necessity. It makes sure you take the administrative route that matches the actual problem.

How do I check whether my exact plan covers Bijuva?

Use the member-specific formulary or drug-pricing tool tied to your own plan. Search both Bijuva strengths, record the tier and every restriction, then ask the pharmacy to run the prescribed strength through the benefit before you pay.

Step 1: Identify the exact pharmacy benefit

Look at:

The prescription card
The back of the medical insurance card
The member portal
The Summary of Benefits and Coverage
A recent pharmacy receipt or Explanation of Benefits

Record the plan name, group name, PBM or drug-benefit administrator, RxBIN, and RxPCN. Do not assume the public formulary attached to the insurer's main website is the document your employer or plan sponsor selected.

Step 2: Search both Bijuva strengths

The current FDA label lists:

0.5 mg estradiol/100 mg progesterone
1 mg estradiol/100 mg progesterone

Plans can handle the strengths differently. The Michigan, Washington, and New York documents in our dataset do. Current FDA/DailyMed Bijuva labeling

Step 3: Write down these eight fields

Covered, excluded, non-formulary, or not found
Exact strength
Tier
Prior authorization
Step therapy
Quantity or age limit
Retail, preferred-pharmacy, or mail-order requirement
Displayed 30-day and 90-day member price

Without those fields, every phone call starts over from zero.

Step 4: Ask the pharmacy to process the exact prescription

A pharmacy generally needs a valid prescription on file to adjudicate the claim. Say:

“Could you run Bijuva at my prescribed strength through my current pharmacy benefit and tell me the adjudicated amount, plus the exact rejection or restriction code if it does not pay? Which NDC did you submit, and would the result change at a preferred pharmacy or with a different day supply?”

Call the plan with the exact questions

“Is Bijuva at [strength] covered under my exact pharmacy benefit? What tier is it? Does it require prior authorization, step therapy, a quantity limit, or an age limit? Is my pharmacy deductible affecting the price? Is there a preferred pharmacy or mail-order rule? If it is excluded or high-tier, what exception process applies?”

Write down the date, representative's name or ID, reference number, answer, and deadline.

Your Bijuva coverage record

Field	Your result
Plan and group
PBM or drug-benefit administrator
Bijuva strength
Formulary status
Tier
PA / ST / QL / age limit
Deductible remaining
Retail price through insurance
Preferred-pharmacy price
Mail-order price
Rejection or denial code
Call reference number
Exception or appeal deadline

A correctly applied deductible is not the same thing as a formulary denial. A claim-processing or benefit error can still be challenged, so ask the plan to explain the calculation rather than accepting “that is your deductible” as the end of the conversation.

How much does Bijuva cost with insurance?

There is no universal Bijuva copay. A covered prescription can still be expensive because the tier, deductible, copay or coinsurance, day supply, pharmacy network, restrictions, and assistance eligibility all affect the final claim.

Variable	What it can change
Deductible	You may owe the plan's negotiated amount before cost sharing begins
Copay versus coinsurance	A fixed dollar amount and a percentage of drug cost can produce very different totals
Tier	The same tier number carries different prices across plans
Day supply	A 30-day and 90-day fill may use different cost-sharing rules
Pharmacy network	Preferred retail, non-preferred retail, and mail order can price differently
Utilization management	A pending PA or other requirement can prevent a covered price from appearing
Assistance eligibility	Commercial and Medicare programs follow different rules
Accumulator treatment	A cash or coupon transaction may not count toward a deductible or out-of-pocket total

Get three separate quotes

Insurance alone: “What is the adjudicated amount through my benefit?”
Insurance plus the current commercial card, if eligible: “What is the final amount after the card, and what portion counts toward my plan accumulators?”
Cash with a current discount price: “What is the price if I do not use insurance?”

Do not assume the lowest counter price is the lowest annual cost. A cash transaction may not count toward your deductible. Under the current Bijuva Medicare Part D Alternative Coupon Program, the purchase does not receive Part D true-out-of-pocket credit.

The current commercial card publishes no guaranteed patient price. It says out-of-pocket cost may vary, maximum limits apply, and pricing may change. Any page presenting one universal insured Bijuva price is giving you a number your own claim can overturn. Current Bijuva commercial copay-card terms

Does Bijuva require prior authorization?

Sometimes. Four public formularies in this dataset display Bijuva without a PA code on the row, while three state-specific UnitedHealthcare documents require PA for at least one strength and a current Mass General Brigham policy sets explicit Bijuva criteria.

Current document	Public PA result
Optum Rx Premium Formulary	No PA code displayed on Bijuva row
Independence Blue Cross Premium Formulary	No PA code displayed on Bijuva row
UnitedHealthcare Commercial PDL	No PA code displayed on Bijuva row
FEP Blue Basic Medicare formulary	No requirement displayed on either Bijuva strength
UnitedHealthcare Michigan Medicaid	PA on both strengths
UnitedHealthcare Washington Apple Health	PA on both strengths
UnitedHealthcare New York Essential Plan	PA on the listed 1 mg/100 mg strength
Mass General Brigham commercial/exchange policy	Bijuva-specific PA criteria

This is the correct conclusion: prior authorization is neither universal nor rare enough to ignore. Check the exact member benefit before the prescription is sent or as soon as the pharmacy returns a PA message.

PA, step therapy, quantity limits, and exclusions are different

Restriction	What it means
Prior authorization	The plan requires information and approval before covered payment
Step therapy	The plan requires use or documentation involving another option first
Quantity limit	The plan caps the amount or day supply it will cover
Age limit	The plan applies an age-based rule to the listed strength
Formulary exclusion	The drug is outside the ordinary covered list
Claim rejection	A pharmacy transaction failed; the reason may be administrative rather than a coverage decision

Get the actual criteria. A generic “Bijuva needs PA” statement cannot tell your prescriber what to submit.

What can a Bijuva prior authorization require?

The current Mass General Brigham commercial and exchange policy provides one verified example. Its standard route requires the member to be 18 or older, have moderate-to-severe vasomotor symptoms due to menopause, and have inadequate response, intolerance, or a contraindication to estrogen and progesterone taken concurrently as separate agents.

Approvals under that policy are granted for 12 months. It also has a separate continuation route for a member new to the plan within the past 90 days who is already receiving Bijuva. In that specific new-member route, product obtained as samples or through a manufacturer patient-assistance program is excluded. Mass General Brigham Bijuva PA policy

That distinction matters. The draft version of this page said samples and coupons never count as a trial. The current policy does not say that. It excludes samples and manufacturer assistance from one continuation route. Your own plan's language controls what counts elsewhere.

The sentence an approval can turn on—under this policy

“Estrogen and progesterone formulation taken concurrently as separate agents.”

Not estrogen alone. Not progesterone alone. Not a local vaginal estrogen product. The criterion describes concurrent separate agents.

Do not manufacture a history to fit it. Do not ask a prescriber to overstate an intolerance. Do make sure an accurate history is actually in the chart and in the submitted record.

Separate-components trial worksheet

Field to document truthfully	Details
Estrogen product and route
Progesterone product and route
Dates used concurrently
Doses prescribed
What happened
Inadequate response, intolerance, or contraindication
Where it appears in the chart
Supporting pharmacy or visit records
Prescriber submitting the request
Plan criterion being answered

A prior authorization is decided on the record the reviewer receives. Accurate treatment history that never reaches the submission cannot help the decision.

Can I use the Bijuva savings card if insurance denied it?

Not against an outright non-covered claim. The current commercial copay card requires an eligible commercial plan that covers a valid Bijuva prescription at the time it is filled. The card reduces an eligible covered out-of-pocket amount; it does not create formulary coverage.

There is one important distinction: if the pharmacy rejection is “prior authorization required,” the plan may cover Bijuva after approval. Once coverage exists and the other terms are met, the card may apply. If the plan's final result is excluded or non-covered, the current card does not satisfy its own coverage requirement.

Current commercial-card terms checked August 3, 2026

Term	What it means at the pharmacy
Commercial insurance required	Marketplace coverage may qualify, but the exact plan must meet the terms
Plan must cover Bijuva at fill	The card cannot override an exclusion
Government programs are excluded	Medicare, Medicare Advantage, Part D, Medigap, Medicaid, TRICARE, VHA, DOD, IHS, and listed state programs are not eligible
Cash-paying patients are excluded	This is not a general cash coupon
Some Medicare-eligible people with employer or retiree drug coverage are excluded	A commercial-looking card does not automatically establish eligibility
Deductible and PA requirements remain	The card does not waive the plan's rules
Maximum reimbursement limits apply	The program does not promise unlimited assistance
No guaranteed patient price is published	The final amount is determined when the claim is processed
The card's value cannot be submitted to an HSA or FSA	That is narrower than saying every remaining patient-paid amount is ineligible
Expiration date	December 31, 2026; valid prescriptions must be filled before expiration
Terms can change	The sponsor may amend or end the offer without notice

Read the current official Bijuva commercial copay-card terms before the prescription is processed.

Here is the gap nobody warns you about: the woman most desperate for a coupon after an exclusion is the woman the current commercial card cannot help until coverage is approved. Do not spend another hour retrying a copay card against a final exclusion.

Your claim result	The productive route
PA missing	Complete the PA, then check card eligibility
Covered but expensive	Compare the card, preferred pharmacy, mail order, and a tiering exception if the plan allows one
Excluded	Request the exception criteria or discuss a covered FDA-approved option with the prescriber
Cash or uninsured	The commercial card is not valid; compare current cash prices
Medicare	Use the Part D section below; the commercial card is not valid

Does Medicare cover Bijuva?

Some Medicare drug plans cover Bijuva and others may not. The FEP Blue Basic Medicare 2026 formulary in this dataset lists both strengths at Tier 3, which proves that a blanket “Medicare never covers Bijuva” claim is wrong. It does not establish coverage under another Part D or Medicare Advantage plan.

The two Bijuva programs are not interchangeable

	Commercial Bijuva copay card	Bijuva Medicare Part D Alternative Coupon Program
Intended coverage	Eligible commercial insurance	Medicare Part D or Medicare Advantage prescription-drug coverage
Does the current program require plan coverage?	Yes, at the time of fill	No; plan noncoverage is one eligibility trigger
Medicare eligible?	No under the listed terms	Yes, subject to the program's conditions
Commercially insured eligible?	Potentially	No
Uninsured eligible?	No	No
Guaranteed patient price published?	No	No
Key trade-off	Deductible, PA, and maximum limits remain	The participant opts out of Part D for Bijuva for the rest of the calendar year

Who can qualify for the Part D alternative program?

The current program says it may apply when a person has Medicare Part D or Medicare Advantage prescription coverage and either:

The plan does not cover Bijuva, or
The plan's out-of-pocket amount exceeds $50 for 30 capsules, $100 for 60 capsules, or $150 for 90 capsules

Those are eligibility thresholds, not promised final prices. Maximum limits apply. Current Bijuva Medicare Part D Alternative Coupon Program

What opting out costs you

Program commitment	Practical consequence
Opt out of using prescription insurance for Bijuva for the rest of the calendar year	You cannot return to the Part D benefit for Bijuva that year even if the benefit changes
Do not submit the Bijuva cost to insurance, HSA, FSA, or another reimbursement account	The program transaction stays outside those reimbursement routes
Do not seek Part D true-out-of-pocket credit	The Bijuva spending does not move you toward the annual Part D out-of-pocket threshold
Notify the plan using the program's opt-out letter	Enrollment includes an administrative step with the Part D plan
Do not combine with another coupon or discount offer	The program is mutually exclusive with other listed savings routes
Pay additional costs after reimbursement limits are reached	The program publishes no unlimited benefit and no guaranteed fill price

For 2026, Medicare says no Part D plan may have a deductible above $615. After the deductible, members generally pay 25% for covered Part D drugs until covered out-of-pocket spending reaches $2,100, after which covered Part D drugs cost $0 for the rest of the calendar year. Medicare's 2026 Part D cost rules

That creates a real trade-off: a lower Bijuva price outside the benefit today can matter less—or cost more over the year—if you are otherwise likely to reach the $2,100 threshold, because the program purchase does not count toward it.

Compare these paths before opting out

Your exact covered Part D price
A Part D formulary or tiering exception
A prescriber-approved covered alternative
The current Bijuva Part D alternative program and its non-TrOOP consequences

Do not enroll until you know the program's current pharmacy price and maximum. The official terms provide the eligibility thresholds and consequences, not a guaranteed final price.

For the broader benefit rules, use our Medicare and HRT guide.

Is there a generic Bijuva?

FDA approved an Amneal estradiol/progesterone 1 mg/100 mg generic in May 2022 and found it bioequivalent and therapeutically equivalent to Bijuva 1 mg/100 mg. DailyMed now lists a January 14, 2026 marketing end date for the associated ANDA record, so approval does not establish current pharmacy availability.

What is verified

FDA approved ANDA 214293 for estradiol/progesterone 1 mg/100 mg on May 16, 2022.
FDA identified it as bioequivalent and therapeutically equivalent to Bijuva 1 mg/100 mg.
We did not verify an FDA-approved 0.5 mg/100 mg generic.
The current Amneal DailyMed record lists NDC 69238-1690-3 and a marketing end date of January 14, 2026.

FDA approval letter for ANDA 214293 · Amneal DailyMed record

What is not verified

We did not verify that a U.S. pharmacy or wholesaler can currently order the Amneal product. A marketing-end record makes it an unreliable assumption, but it does not let this page report the inventory of every pharmacy.

Ask the pharmacist:

“Can you check whether Amneal estradiol/progesterone 1 mg/100 mg, NDC 69238-1690-3, is currently orderable through your wholesaler? DailyMed lists a January 14, 2026 marketing end date, so please verify the current status rather than assuming.”

Approved is not the same as currently marketed. That is the clean answer to the generic contradiction.

Separate FDA-approved estradiol and progesterone prescriptions are a different regimen selected by the prescriber. They are not the FDA-approved generic product identified in ANDA 214293 and are not an automatic pharmacy substitute for Bijuva.

What should I do if insurance denies Bijuva?

Start by getting the exact pharmacy rejection and the written plan reason. A missing PA, formulary exclusion, high tier, early refill, wrong pharmacy, coordination-of-benefits problem, and unrecognized NDC are different problems and require different fixes.

What you are told	What it may mean	Ask this next
“Prior authorization required”	The plan has not yet approved the required review	“Where are the current criteria, and has the request been sent to my prescriber?”
“Not covered” or “not on formulary”	Exclusion, non-formulary status, wrong benefit, or another rule	“What is the written reason, and is a formulary exception available?”
“Refill too soon”	Timing rather than formulary coverage	“What is the next eligible fill date?”
“Deductible not met”	The claim may be covered while you owe the negotiated amount	“What is my remaining pharmacy deductible, and how was this amount calculated?”
“Out of network”	The pharmacy is outside the plan's network or preferred network, which can change whether the claim pays and what you owe	“Which nearby pharmacies are in network or preferred?”
Wrong insurance or COB	The wrong benefit or order of coverage was submitted	“Which plan did you bill, and can you rerun the current card?”
“NDC not covered”	The submitted package code may not match the plan file	“Which NDC did you submit, and what current Bijuva NDC will the plan recognize?”
High Tier 3 amount	Coverage exists, but cost sharing is high	“Does this plan permit a tiering exception, and what preferred-pharmacy or mail-order prices apply?”

The current Bijuva NDC record contains a discrepancy worth knowing

DailyMed's current Bijuva page lists the 30-count carton codes as:

50261-251-30 for 0.5 mg/100 mg
50261-211-30 for 1 mg/100 mg

The same current record shows a November 7, 2024 marketing end date for the 1 mg/100 mg 30-count package code while still displaying that NDC on the current label; it also lists a 5-count package code without that end date. The public record does not explain what a specific wholesaler or pharmacy will supply. Current Bijuva DailyMed record

Do not turn that discrepancy into “Bijuva is discontinued” or “the plan denied the drug.” Ask the pharmacist which NDC was submitted, which current package is orderable, and which code the plan recognizes.

Work the denial in this order

Get it in writing. Save the pharmacy response, denial notice, claim code, date, and reference number.
Rule out processing problems. Wrong card, wrong day supply, early refill, wrong quantity, out-of-network pharmacy, COB, expired PA, or NDC mismatch.
Match the route to the reason. PA submission, step-therapy documentation, quantity exception, formulary exception, tiering exception, or corrected claim.
Use the deadline on the notice. Do not rely on a generic web deadline when your plan document gives a specific one.
Compare a covered FDA-approved option with the prescriber if the denial stands.

For health plans subject to the federal internal-appeal process described by HealthCare.gov, an internal appeal generally must be filed within 180 days of the denial notice. Plan type and state rules can differ, so follow the actual notice. HealthCare.gov internal-appeal guidance

What does a decided Bijuva appeal show?

A published 2020 New York external appeal shows what happens when the submitted record does not answer the formulary criterion. The denial was upheld because the reviewed record did not show a trial and failure of the formulary alternative, and irritation from Estrace cream did not establish adverse events with the alternatives the reviewer considered.

In New York case 202008-130851:

The plan was MetroPlus Health Plan.
The appeal type was a formulary exception.
Bijuva was non-formulary.
The patient reported irritation after a three-month Estrace cream trial.
The reviewer found no documented adverse events with the formulary alternatives and noted that estradiol and progesterone were on formulary.
The denial was upheld.

New York State external appeal 202008-130851

This is a historical case, not a current universal Bijuva rule. Its practical lesson still matters: documentation adjacent to a criterion is not the same as documentation that satisfies it. The submitted Estrace cream experience did not answer the plan's estradiol-and-progesterone alternative evidence in that review.

To the reviewer, a reaction that was not in the submitted medical record could not carry the appeal.

How do I request the right exception or appeal?

Use the request that matches the problem. Medicare Part D uses defined coverage-determination and exception categories; commercial and Medicaid processes vary by plan and state, so the denial notice and benefit documents control.

Medicare Part D request types

Request	Use it when
Coverage determination	You need the Part D plan to decide whether and how it will cover the prescription
Formulary exception	Bijuva is not on the formulary, or you are asking the plan to waive a PA, step, or quantity rule
Tiering exception	Bijuva is covered at a non-preferred tier and the plan's rules permit a request for preferred cost sharing
Redetermination	The Part D plan already issued an unfavorable coverage determination

CMS says a prescriber must provide a supporting statement for a Part D exception. Once the plan receives that statement for a benefit request, it must provide a decision within 72 hours for a standard request or 24 hours for an expedited request. Those clocks apply to Part D exception processing; they are not a universal commercial-insurance PA deadline. CMS Part D exception guidance

A Part D supporting statement may need to explain why covered alternatives would not be as effective, would cause adverse effects, or why a utilization-management requirement should be waived. Use the plan's current form or criteria and keep the history factual.

Commercial or marketplace appeal

Follow the denial notice. Keep:

The denial and Explanation of Benefits
The pharmacy rejection
The exact formulary and PA criteria
The prescription and strength
The prescriber's supporting records
Notes from every call
Submission confirmation
The appeal deadline

Do not ask a clinician to write that every alternative failed if that did not happen. Ask the plan what evidence it requires and submit the evidence that actually exists.

What alternatives might insurance prefer instead of Bijuva?

The reviewed Express Scripts, Aetna, and Optum documents repeatedly point toward generic estradiol/norethindrone acetate or separately listed estrogen and progesterone products, but the preferred option changes across formularies. A plan's preference is a coverage position—not proof that another product is clinically equivalent or right for you.

Option in the reviewed documents	What the paperwork shows
Estradiol/norethindrone acetate	Preferred alternative on the Express Scripts exclusion list; preferred option on the Aetna exclusion list; Tier 1 on the Optum formulary
Oral estradiol	Tier 1 on the Optum formulary
Oral progesterone	Tier 1 on the Optum formulary
Premphase and Prempro	Excluded on the Express Scripts and Aetna documents; Tier 2 on Optum
Duavee	Excluded on the Aetna document; Tier 2 on Optum
Bijuva	Excluded on Express Scripts; preferred option on Aetna; Tier 3 on Optum

That table is why no responsible page should give you one universal list of “covered Bijuva alternatives.”

Ask the prescriber:

Is the plan's option the same route and dosing structure?
Is it one FDA-approved combination or separate FDA-approved products?
Does the alternative fit the reason for treatment and my medical history?
Is an exception more appropriate than switching?
What changes in follow-up or monitoring?

Bijuva is an FDA-approved prescription product. A compounded estradiol/progesterone preparation is not generic Bijuva, is not FDA-approved, and is not reviewed by FDA for safety, effectiveness, or quality before marketing. Do not present compounded and FDA-approved products as equivalent or interchangeable. FDA compounding questions and answers

For a broader price comparison of FDA-approved options, use our 2026 HRT cost guide.

Where does online menopause care fit?

An online clinician can evaluate, prescribe when appropriate, and document a visit. No telehealth provider can guarantee that a plan will cover Bijuva, waive its formulary, approve a PA, or accept an appeal.

Before paying for online care, ask:

Do clinicians prescribe or continue FDA-approved Bijuva when medically appropriate?
Is the service available in my state?
Does it bill my exact insurance plan, or is the visit self-pay?
Will the clinical team submit Bijuva prior authorization?
Will it respond to an appeal or exception request?
Are labs required, and are they included or separately billed?
What will the initial visit, follow-up, and refill support cost?
What are the cancellation and medication-continuation terms?

We did not verify a specific provider against those eight questions for this page, so no provider is presented as the Bijuva coverage winner.

If the bottleneck is bigger than one claim—provider model, insurance, state, route, symptoms, or whether online care fits at all—use Find My HRT Path before paying for a consult.

The HRT Index may earn a commission from some links. No insurer, PBM, manufacturer, or provider supplied the coverage conclusions on this page. See our affiliate disclosure.

What changed in Bijuva's FDA label in 2026?

The current FDA label removed the boxed-warning sections for cardiovascular disorders, probable dementia, breast cancer, and endometrial cancer in February 2026. The contraindications and risk discussions did not disappear; the current label still contains cardiovascular and malignant-neoplasm warnings and lists the product's contraindications.

The current label describes Bijuva as an estrogen-and-progesterone capsule for a woman with a uterus for moderate-to-severe vasomotor symptoms due to menopause. It lists 0.5 mg/100 mg and 1 mg/100 mg strengths and directs one capsule each evening with food. Current FDA Bijuva prescribing information

The brand website and current label do not match

As checked August 3, 2026, Bijuva's official cost-and-savings page still displayed the former boxed-warning block and labeled its prescribing-information link as including a boxed warning. The linked current FDA/DailyMed label says the boxed-warning sections were removed in February 2026. Bijuva cost-and-savings page · Current Bijuva DailyMed label

For current prescribing information, use the current FDA or DailyMed label rather than a stale safety block on a marketing page.

Removing the boxed warning did not make Bijuva risk-free, determine whether it is right for an individual, or change any formulary in this dataset. This page is about access and payment—not whether to start, stop, or change treatment.

How did The HRT Index verify this page?

This page is built from 10 current insurance documents, current official Bijuva commercial and Medicare program terms, current FDA and DailyMed records, Medicare rules, federal appeal guidance, and a published state appeal. No member-specific pharmacy claim was run.

Our review process is The HRT Index Verification Standard—the documented process by which The HRT Index reads every published price, separates FDA-approved from compounded options, verifies state availability and insurance information, and re-checks material claims on a fixed schedule.

The five pillars are always evaluated in this order:

Clinical legitimacy
Care quality
Medication fit
Price transparency
Access

It is not a numeric score, and this page does not invent a score for Bijuva, an insurer, or a provider.

Who, how, and why

Who: The HRT Index Editorial Team.

How: Direct review of the named primary documents on August 2–3, 2026, with each plan result limited to the exact document and strength shown.

Why: A woman standing at a pharmacy counter with a rejection or unaffordable price deserves a better answer than “coverage varies.”

Review status: Editorial research. Not medically reviewed by a clinician. Educational only—not medical advice.

Re-verification schedule

Item	Refresh cadence	Trigger
Commercial and state formularies	Quarterly, plus January 1 and July 1 checks	New plan year, midyear update, tier or restriction change
Commercial copay-card terms	Monthly	Expiration, eligibility, maximum, or program-term change
Medicare Part D alternative program	Monthly	Threshold, opt-out, TrOOP, eligibility, or price-term change
Medicare cost rules	At least annually and after CMS updates	Deductible or out-of-pocket threshold change
FDA and DailyMed Bijuva label	Quarterly and event-driven	Label, indication, warning, strength, or package change
Amneal generic marketing status	Monthly until resolved	New NDC, relaunch, discontinuation update, or verified wholesaler availability
Provider access claims	Top providers monthly; full roster quarterly	State, insurance, medication, lab, pricing, or cancellation change
Internal tools and links	Every page release	Broken link, privacy change, or tool-output change

The “Last verified” date changes only after the material claims are rechecked.

Primary-source ledger

What should I do next?

Find your result. Take the matching action. Do not restart the research from zero.

Your result	Your next action
Covered and affordable	Fill as prescribed and save the current formulary result for renewal
Covered but expensive, commercial plan	Compare preferred-pharmacy and mail-order pricing; check the current card; ask whether a tiering exception exists
Covered but expensive, Medicare	Compare the Part D price, exception route, and opt-out program's non-TrOOP consequences before enrolling
PA required	Get the current criteria and ask whether the prescriber's office will submit the required record
ST required	Get the actual step rule in writing and document only the treatment history that occurred
QL or age limit	Confirm the prescription and request the plan's exception criteria if needed
Excluded	Get the written reason; compare a formulary exception with a prescriber-approved covered option; stop retrying the commercial card
Not found	Search both strengths, call the pharmacy-benefit line, and run the exact prescription
NDC rejection	Ask which NDC was billed and have the pharmacy verify a current package code
Uninsured	Compare current cash prices at several pharmacies; the two manufacturer programs verified here do not apply
Still unsure what care path fits	Use Find My HRT Path

Frequently asked questions

Does insurance cover Bijuva?

Sometimes. In the current documents reviewed for this page, Bijuva ranged from excluded, to a preferred option, to Tier 2 or Tier 3 with different restrictions. The exact member benefit determines the final result.

What tier is Bijuva?

There is no universal tier. It is Tier 3 on the reviewed Optum Rx, Independence Blue Cross, UnitedHealthcare commercial, and FEP Blue Basic Medicare documents; Tier 2 with restrictions on three reviewed state-specific UnitedHealthcare documents; a preferred option on the Aetna exclusion list; and excluded on the Express Scripts National Preferred Formulary exclusion list.

Does UnitedHealthcare cover Bijuva?

Some reviewed UnitedHealthcare documents list it, but the rules differ. The commercial PDL shows Tier 3 with no row restriction code, Michigan Medicaid and Washington Apple Health list both strengths at Tier 2 with PA, and the New York Essential Plan lists the 1 mg/100 mg strength at Tier 2 with PA and QL.

Does Aetna cover Bijuva?

The July 2026 Aetna Advanced Control Plan exclusion list names Bijuva as a preferred option for excluded Angeliq, Duavee, Premphase, and Prempro. That does not establish Bijuva's tier, restrictions, price, or coverage under every Aetna plan.

Does Express Scripts cover Bijuva?

The reviewed 2026 Express Scripts National Preferred Formulary exclusion list excludes Bijuva and lists alternatives. Express Scripts administers other plan designs, so confirm the exact formulary attached to your membership.

Does Blue Cross Blue Shield cover Bijuva?

Blue plans are not interchangeable. The reviewed Independence Blue Cross Premium Formulary lists Bijuva at Tier 3, and the FEP Blue Basic Medicare formulary lists both strengths at Tier 3. Another Blue plan can differ.

Does Cigna cover Bijuva?

We did not verify a current Cigna-specific Bijuva plan document for this page. Check the exact Cigna member formulary or prescription-price tool rather than inferring coverage from another plan.

Does Medicare cover Bijuva?

Some plans do. The reviewed FEP Blue Basic Medicare 2026 formulary lists both strengths at Tier 3. That is one plan-specific example, not a national Medicare coverage rate.

Does Medicaid cover Bijuva?

It depends on the state and managed-care plan. The reviewed UnitedHealthcare Michigan and Washington Medicaid documents list both strengths at Tier 2 with PA, but their other restrictions differ. The commercial Bijuva card is not valid for Medicaid.

Does Bijuva require prior authorization?

Sometimes. Several current public formulary rows reviewed here show no PA code, while three state-specific UnitedHealthcare documents and the current Mass General Brigham policy require PA. Check the exact strength and benefit.

Can I use the Bijuva savings card if insurance denied it?

Not if the final result is an uncovered or excluded claim. The current commercial card requires the plan to cover Bijuva at the time of fill. If the rejection is a missing PA and the plan later approves coverage, the card may apply if every other term is met.

Can I use the Bijuva savings card with Medicare?

The commercial card is not valid for Medicare, Medicare Advantage, Part D, or Medigap under its current terms. A separate Bijuva Part D alternative program exists, but it requires opting out of the Part D benefit for Bijuva for the rest of the calendar year.

Is there a generic Bijuva?

FDA approved an Amneal generic of the 1 mg/100 mg strength in May 2022. DailyMed lists a January 14, 2026 marketing end date for that ANDA record, so current orderability must be verified with the pharmacy or wholesaler. We did not verify a 0.5 mg/100 mg generic.

How much does Bijuva cost without insurance?

There is no reliable national cash price. Cash and discount quotes vary by ZIP code, pharmacy, date, and session. Check several current quotes and ask whether paying cash will affect your deductible or out-of-pocket tracking.

Can I take separate estradiol and progesterone instead?

That is a prescriber decision. Separate FDA-approved products are not the same pharmacy product as Bijuva and are not the Amneal FDA-approved generic identified in ANDA 214293.

Can I pay for Bijuva with an HSA or FSA?

The current commercial-card terms say the value received from the card cannot be submitted to an HSA or FSA. Whether a remaining patient-paid expense is eligible is a separate question for the account administrator.

How long does a Bijuva prior authorization take?

Commercial and Medicaid timing varies by plan. For a Medicare Part D exception benefit request, CMS says the plan must decide within 72 hours for a standard request or 24 hours for an expedited request after receiving the prescriber's supporting statement.

What if the pharmacy says the Bijuva NDC is not covered?

Ask which NDC was submitted. Have the pharmacist verify the currently orderable Bijuva package code and ask the plan which code it recognizes before treating the message as a drug-level exclusion.

Before you close this tab

Three things, if you take nothing else:

Find the exact pharmacy benefit—not just the insurer logo.
Get the rejection, restriction, or denial reason in writing before you pay cash or appeal.
Use the route that matches the result: corrected claim, PA, exception, eligible card, Medicare comparison, or prescriber-approved alternative.

You are not being difficult for asking a plan to explain what it will pay for and why. You are doing the thing that turns a vague “no” into an answer you can act on.

Still not sure which HRT program is right for you? Take our free 60-second matching quiz.

→ Find My HRT Path

Last verified August 3, 2026. Formulary status, program terms, Medicare rules, packaging records, and prices can change. The Bijuva commercial copay card reviewed for this page expires December 31, 2026.

Need a broader HRT coverage comparison?

Start with the HRT insurance coverage guide or compare current medication prices in the 2026 HRT cost guide.

Keep reading: